View ValuationEntheon Biomedical 将来の成長Future 基準チェック /06現在、 Entheon Biomedicalの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長25.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Dec 23Entheon Biomedical Corp. (CNSX:ENBI) signed a letter of intent to acquire Entheon Biomedical Corp. for CAD 5.33 million in a reverse merger transaction.Nutravisor Inc. signed a letter of intent to acquire Entheon Biomedical Corp. (CNSX:ENBI) for CAD 5.33 million in a reverse merger transaction on December 18, 2025. Under the terms of the LOI, Entheon has agreed to issue an aggregate of 53,333,333 shares of Entheon to existing shareholders of Nutravisor at a per share price equal to CAD 0.75 for aggregate consideration equal to approximately CAD 40 million on a post-consolidation basis. Entheon shall be required to complete an approximately 6.93:1 share consolidation such that the value allocated to Entheon shareholders shall be CAD 1.5 million. A finder's fee in the amount of CAD 0.5 million is being paid in connection with the Proposed Transaction. Upon completion of the Proposed Transaction, the combined entity will continue the business of Nutravisor. Following the transaction, Nutravisor's existing management team will assume leadership of the Resulting Issuer. All but one of the directors of Entheon shall resign and the board of directors will be comprised of directors nominated by Nutravisor. Entheon is expected to change its name concurrent with closing, subject to regulatory approval. The Definitive Agreement is expected to be executed in January, 2026. The LOI contains customary deal protection provisions, including a mutual break fee in the amount of CAD 0.04 million payable if the Proposed Transaction is terminated by either party under certain specific circumstances. A finder's fee in the amount of CAD 0.5 million is being paid in connection with the Proposed Transaction. The transaction is expected to close on or before March 30, 2026, subject to satisfactory tax, corporate and securities law advice for both Entheon and Nutravisor and will be set forth in a definitive agreement to be entered into among the parties, Execution of the Definitive Agreement, Completion of satisfactory due diligence, Receipt of all required regulatory, corporate, and shareholder approvals, Acceptance of the Proposed Transaction by the Canadian Securities Exchange, Receipt of approval for the listing of the common shares of the Resulting Issuer by the CSE, Completion of the Concurrent Offering, Delivery of financial statements of both Entheon and Nutravisor; and No material adverse changes in either party.お知らせ • Oct 14Entheon Biomedical Corp., Annual General Meeting, Dec 15, 2025Entheon Biomedical Corp., Annual General Meeting, Dec 15, 2025.お知らせ • Apr 08Entheon Biomedical Corp. Announces Board ChangesEntheon Biomedical Corp. appointed Harrison Newlands to the Company's Board of Directors, effective April 3, 2025. Harrison Newlands has a diverse understanding of start-ups and capital markets, having invested, advised, and helped co-found dozens of mid-cap companies spanning close to a decade of experience in the industry. He started his career working on Bay Street as a Research Associate at MacNicol and Associates, thereafter he jumped into the fast growing cannabis industry, and was one of the co-founders of Fire & Flower, one of Canada's first retail focused cannabis companies, where he led its early growth and served as Director of Business Development. Shortly thereafter, he helped take the first EV company public in Canada, Taiga Motors, where he served as a strategic advisor. Mr. Newlands also co-founded Hoshi International, a producer of medicinal cannabis with a state of the art facility in Portugal, focusing on the emerging European market. Harrison also co-founded Hypercharge Networks, Canada's first publicly traded EV charging company. Harrison was formerly a partner at Rockbank Capital, a Vancouver based merchant bank, and has been a managing partner at North King Capital over the past 4 years, where he continues to advise both public and private companies, as well as invest. Andrew Hegle has resigned from the Company's Board of Directors.お知らせ • Jan 07Entheon Biomedical Corp. announced that it has received CAD 0.5 million in fundingOn January 6, 2025. Entheon Biomedical Corp. closed the transaction.お知らせ • Dec 03Entheon Biomedical Corp. announced that it expects to receive CAD 0.3 million in fundingEntheon Biomedical Corp. announced a non-brokered private placement of 30,000,000 units at a price of CAD 0.1 per unit for gross proceeds of CAD 3,000,000 on December 2, 2024. Each unit consists of one common share of the company and one transferable share purchase warrant, with each warrant exercisable for one additional share at an exercise price of CAD 0.15 per share for a period of 24 months from the date of issuance. All securities to be issued will be subject to a four-month and a day hold period. The Company may pay finder's fees in accordance with the policies of the Canadian Securities Exchange.お知らせ • Oct 15Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024. Location: vancouver Canadaお知らせ • Apr 20Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in fundingOn April 18, 2024, Entheon Biomedical Corp. closed the transaction. All securities issued under the placement are subject to a hold period of four months and one day expiring on Aug. 19, 2024.お知らせ • Apr 12Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in fundingEntheon Biomedical Corp. announced a private placement of up to 2,950,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 147,500 on April 11, 2024. Each unit will consist of one common share and one transferable share purchase warrant. Each warrant will be exercisable to acquire one additional share at an exercise price of CAD 0.10 per share for a period of 60 months from the date of issuance. All securities issued under the placement will be subject to a four-month and one-day hold period. The company may pay finder’s fees in accordance with the policies of the Canadian Securities Exchange.お知らせ • Oct 31Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023. Location: Vancouver Vancouver Canadaお知らせ • Aug 01Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science OfficerEntheon Biomedical Corp. announced that the company has terminated Andrew Hegle's position as Chief Science Officer, effective July 31, 2023. Mr. Hegle will continue on the Company's Board of Directors.お知らせ • Feb 18Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023.お知らせ • Jan 07Entheon Biomedical Corp. Announces CFO ChangesEntheon Biomedical Corp. announced the appointment of Soo-Whan Kim as Interim Chief Financial Officer of the Company, effective immediately. Mr. Kim brings over 12 years of experience working in senior finance positions of publicly traded companies. Mr. Kim serves as the Chief Financial Officer of Western Metallica Resources Corp. and as Corporate Controller of Consolidated Uranium and Labrador Uranium. He was previously Director of Treasury & Planning at Americas Gold & Silver and Corporate Controller at Andean Precious Metals and Polar Star Mining. Mr. Kim began his career at BDO Canada where he worked with numerous companies across various sectors. Mr. Kim is a Chartered Professional Accountant (CPA, CA) and holds a Bachelor of Commerce from the Ted Rogers School of Management at Toronto Metropolitan University. Mr. Kim replaces Brandon Schwabe as Chief Financial Officer. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Entheon Biomedical は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:ENTB.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数8/31/2025N/A000N/A5/31/2025N/A000N/A2/28/2025N/A000N/A11/30/2024N/A000N/A8/31/2024N/A000N/A5/31/2024N/A000N/A2/29/20240000N/A11/30/20230000N/A8/31/20230000N/A5/31/20230000N/A2/28/20230-1-1-1N/A11/30/20220-2-2-2N/A8/31/20220-3-3-3N/A5/31/20220-5-4-4N/A2/28/2022N/A-7-4-4N/A11/30/2021N/A-8-5-5N/A8/31/20210-10-6-6N/A5/31/20210-9-6-6N/A2/28/2021N/A-7-5-5N/A11/30/2020N/A-4-3-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ENTB.Fの予測収益成長が 貯蓄率 ( 3.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ENTB.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ENTB.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ENTB.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ENTB.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ENTB.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/17 00:06終値2025/12/18 00:00収益2025/08/31年間収益2024/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Entheon Biomedical Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 23Entheon Biomedical Corp. (CNSX:ENBI) signed a letter of intent to acquire Entheon Biomedical Corp. for CAD 5.33 million in a reverse merger transaction.Nutravisor Inc. signed a letter of intent to acquire Entheon Biomedical Corp. (CNSX:ENBI) for CAD 5.33 million in a reverse merger transaction on December 18, 2025. Under the terms of the LOI, Entheon has agreed to issue an aggregate of 53,333,333 shares of Entheon to existing shareholders of Nutravisor at a per share price equal to CAD 0.75 for aggregate consideration equal to approximately CAD 40 million on a post-consolidation basis. Entheon shall be required to complete an approximately 6.93:1 share consolidation such that the value allocated to Entheon shareholders shall be CAD 1.5 million. A finder's fee in the amount of CAD 0.5 million is being paid in connection with the Proposed Transaction. Upon completion of the Proposed Transaction, the combined entity will continue the business of Nutravisor. Following the transaction, Nutravisor's existing management team will assume leadership of the Resulting Issuer. All but one of the directors of Entheon shall resign and the board of directors will be comprised of directors nominated by Nutravisor. Entheon is expected to change its name concurrent with closing, subject to regulatory approval. The Definitive Agreement is expected to be executed in January, 2026. The LOI contains customary deal protection provisions, including a mutual break fee in the amount of CAD 0.04 million payable if the Proposed Transaction is terminated by either party under certain specific circumstances. A finder's fee in the amount of CAD 0.5 million is being paid in connection with the Proposed Transaction. The transaction is expected to close on or before March 30, 2026, subject to satisfactory tax, corporate and securities law advice for both Entheon and Nutravisor and will be set forth in a definitive agreement to be entered into among the parties, Execution of the Definitive Agreement, Completion of satisfactory due diligence, Receipt of all required regulatory, corporate, and shareholder approvals, Acceptance of the Proposed Transaction by the Canadian Securities Exchange, Receipt of approval for the listing of the common shares of the Resulting Issuer by the CSE, Completion of the Concurrent Offering, Delivery of financial statements of both Entheon and Nutravisor; and No material adverse changes in either party.
お知らせ • Oct 14Entheon Biomedical Corp., Annual General Meeting, Dec 15, 2025Entheon Biomedical Corp., Annual General Meeting, Dec 15, 2025.
お知らせ • Apr 08Entheon Biomedical Corp. Announces Board ChangesEntheon Biomedical Corp. appointed Harrison Newlands to the Company's Board of Directors, effective April 3, 2025. Harrison Newlands has a diverse understanding of start-ups and capital markets, having invested, advised, and helped co-found dozens of mid-cap companies spanning close to a decade of experience in the industry. He started his career working on Bay Street as a Research Associate at MacNicol and Associates, thereafter he jumped into the fast growing cannabis industry, and was one of the co-founders of Fire & Flower, one of Canada's first retail focused cannabis companies, where he led its early growth and served as Director of Business Development. Shortly thereafter, he helped take the first EV company public in Canada, Taiga Motors, where he served as a strategic advisor. Mr. Newlands also co-founded Hoshi International, a producer of medicinal cannabis with a state of the art facility in Portugal, focusing on the emerging European market. Harrison also co-founded Hypercharge Networks, Canada's first publicly traded EV charging company. Harrison was formerly a partner at Rockbank Capital, a Vancouver based merchant bank, and has been a managing partner at North King Capital over the past 4 years, where he continues to advise both public and private companies, as well as invest. Andrew Hegle has resigned from the Company's Board of Directors.
お知らせ • Jan 07Entheon Biomedical Corp. announced that it has received CAD 0.5 million in fundingOn January 6, 2025. Entheon Biomedical Corp. closed the transaction.
お知らせ • Dec 03Entheon Biomedical Corp. announced that it expects to receive CAD 0.3 million in fundingEntheon Biomedical Corp. announced a non-brokered private placement of 30,000,000 units at a price of CAD 0.1 per unit for gross proceeds of CAD 3,000,000 on December 2, 2024. Each unit consists of one common share of the company and one transferable share purchase warrant, with each warrant exercisable for one additional share at an exercise price of CAD 0.15 per share for a period of 24 months from the date of issuance. All securities to be issued will be subject to a four-month and a day hold period. The Company may pay finder's fees in accordance with the policies of the Canadian Securities Exchange.
お知らせ • Oct 15Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024Entheon Biomedical Corp., Annual General Meeting, Dec 16, 2024. Location: vancouver Canada
お知らせ • Apr 20Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in fundingOn April 18, 2024, Entheon Biomedical Corp. closed the transaction. All securities issued under the placement are subject to a hold period of four months and one day expiring on Aug. 19, 2024.
お知らせ • Apr 12Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in fundingEntheon Biomedical Corp. announced a private placement of up to 2,950,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 147,500 on April 11, 2024. Each unit will consist of one common share and one transferable share purchase warrant. Each warrant will be exercisable to acquire one additional share at an exercise price of CAD 0.10 per share for a period of 60 months from the date of issuance. All securities issued under the placement will be subject to a four-month and one-day hold period. The company may pay finder’s fees in accordance with the policies of the Canadian Securities Exchange.
お知らせ • Oct 31Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023. Location: Vancouver Vancouver Canada
お知らせ • Aug 01Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science OfficerEntheon Biomedical Corp. announced that the company has terminated Andrew Hegle's position as Chief Science Officer, effective July 31, 2023. Mr. Hegle will continue on the Company's Board of Directors.
お知らせ • Feb 18Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023.
お知らせ • Jan 07Entheon Biomedical Corp. Announces CFO ChangesEntheon Biomedical Corp. announced the appointment of Soo-Whan Kim as Interim Chief Financial Officer of the Company, effective immediately. Mr. Kim brings over 12 years of experience working in senior finance positions of publicly traded companies. Mr. Kim serves as the Chief Financial Officer of Western Metallica Resources Corp. and as Corporate Controller of Consolidated Uranium and Labrador Uranium. He was previously Director of Treasury & Planning at Americas Gold & Silver and Corporate Controller at Andean Precious Metals and Polar Star Mining. Mr. Kim began his career at BDO Canada where he worked with numerous companies across various sectors. Mr. Kim is a Chartered Professional Accountant (CPA, CA) and holds a Bachelor of Commerce from the Ted Rogers School of Management at Toronto Metropolitan University. Mr. Kim replaces Brandon Schwabe as Chief Financial Officer.